Compare EQPT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQPT | APGE |
|---|---|---|
| Founded | 2015 | 2022 |
| Country | United States | United States |
| Employees | 8206 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | EQPT | APGE |
|---|---|---|
| Price | $19.08 | $132.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $38.88 | ★ $109.67 |
| AVG Volume (30 Days) | 2.3M | ★ 5.1M |
| Earning Date | 03-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.53 | N/A |
| Revenue Next Year | $23.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.95 | $34.34 |
| 52 Week High | $35.50 | $133.85 |
| Indicator | EQPT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 81.44 |
| Support Level | $18.71 | $73.70 |
| Resistance Level | $26.64 | $133.16 |
| Average True Range (ATR) | 1.71 | 1.68 |
| MACD | -0.33 | 2.74 |
| Stochastic Oscillator | 6.18 | 98.29 |
EquipmentShare.com Inc is a vertically integrated platform that combines proprietary technology, a connected equipment fleet, and a nationwide footprint to serve the construction industry. The company operates its business through the following reportable segments: Equipment Rental and Services Operations, comprised of recurring activity performed at full-service branch locations, such as equipment rentals and related services, and sales of parts, supplies, and maintenance services to construction contractors and others. Equipment Sales, sales of new or used equipment made at any of the branch locations and dealership sites, including equipment sales to participants in the OWN Program.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.